“Breast Cancer Talk” Review of Data from the SABCS 2020 Virtual Meeting - Episode 2

Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

January 27, 2021

William J. Gradishar, MD, Northwestern University, Priyanka Sharma, MD, University of Kansas Cancer Center, Pavani Chalasani, MD, University of Arizona Cancer Center

EP. 1: Metastatic Hormone-Receptor Positive Breast Cancer

Now Viewing

EP. 2: Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

EP. 3: Metastatic Triple-Negative Breast Cancer

Breast cancer experts review data from the virtual San Antonio Breast Cancer Symposium 2020 in hormone epidermal growth factor receptor 2-positive breast cancer, then discuss the DESTINY-Breast01, HER2CLIMB, and NALA trials.

Data from the following abstracts are discussed:

“Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer” (Modi et al, 2020)
“GS1-03. [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)” (Krop et al, SABCS 2019)
“PD3-06. Updated Results From DESTINY-Breast01, A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic BreastCancer” (Modietal, SABCS 2020)
“CNS Metastases in HER2-Positive Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan: DESTINY-Breast01 Subgroup Analyses (Jerusalem et al, ESMO Breast 2020)
“Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer” (Murthy et al, 2020)
“Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)” (Curigliano et al, ESMO Breast 2020, 137O)
“Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients With Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases (HER2CLIMB)” (Lin et al, ASCO 2020)
“PD13-04. Impact of Tucatinib on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer With Stable and Active Brain Metastases” (Wardley et al, SABCS 2020 PD-1304)
“Neratinib + Capecitabine Versus Lapatinib + Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Findings From the Multinational, Randomized, Phase III NALA Trial” (Saura et al, ASCO 2019)
“PS9-02. Neratinib + Capecitabine Sustains Health-Related Quality of Life (HRQoL) While Improving Progression-Free Survival (PFS) in Patients With HER2-Positive Metastatic Breast Cancer and ≥2 Prior HER2-Directed Regimens” (Moy et al, SABCS 2020 PS9-02)
“Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-Low Breast Cancer That Has Spread or Cannot Be Surgically Removed [DESTINY-Breast04]” (NCT03734029)

Metastatic Hormone Epidermal Growth Factor Receptor 2-Positive Breast Cancer

Data from the following abstracts are discussed:

“Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer” (Modi et al, 2020)

“GS1-03. [Fam-] Trastuzumab Deruxtecan (T-DXd; DS-8201a) in Subjects With HER2-Positive Metastatic Breast Cancer Previously Treated With T-DM1: A Phase 2, Multicenter, Open-Label Study (DESTINY-Breast01)” (Krop et al, SABCS 2019)

“PD3-06. Updated Results From DESTINY-Breast01, A Phase 2 Trial of Trastuzumab Deruxtecan (T-DXd) in HER2-Positive Metastatic BreastCancer” (Modietal, SABCS 2020)

“CNS Metastases in HER2-Positive Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan: DESTINY-Breast01 Subgroup Analyses (Jerusalem et al, ESMO Breast 2020)

“Tucatinib, Trastuzumab, and Capecitabine for HER2-Positive Metastatic Breast Cancer” (Murthy et al, 2020)

“Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine in Previously Treated HER2-Positive Metastatic Breast Cancer With and Without Brain Metastases (HER2CLIMB)” (Curigliano et al, ESMO Breast 2020, 137O)

“Tucatinib Versus Placebo Added to Trastuzumab and Capecitabine for Patients With Previously Treated HER2-Positive Metastatic Breast Cancer With Brain Metastases (HER2CLIMB)” (Lin et al, ASCO 2020)

“PD13-04. Impact of Tucatinib on Health-Related Quality of Life in Patients With HER2-Positive Metastatic Breast Cancer With Stable and Active Brain Metastases” (Wardley et al, SABCS 2020 PD-1304)

“Neratinib + Capecitabine Versus Lapatinib + Capecitabine in Patients With HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Findings From the Multinational, Randomized, Phase III NALA Trial” (Saura et al, ASCO 2019)

“PS9-02. Neratinib + Capecitabine Sustains Health-Related Quality of Life (HRQoL) While Improving Progression-Free Survival (PFS) in Patients With HER2-Positive Metastatic Breast Cancer and ≥2 Prior HER2-Directed Regimens” (Moy et al, SABCS 2020 PS9-02)

“Trastuzumab Deruxtecan (DS-8201a) Versus Investigator’s Choice for HER2-Low Breast Cancer That Has Spread or Cannot Be Surgically Removed [DESTINY-Breast04]” (NCT03734029)